Notably, HuidaGene Therapeutics has launched two first-in-human Cas13 programs: the HERO trial, evaluating HG204 for MECP2 Duplication Syndrome (MDS), and the SIGHT-I and BRIGHT trials, testing HG202 for neovascular age-related macular degeneration (nAMD). Here, MECP2 is linked to myelodysplastic syndrome.